Investing.com - Incyte (NASDAQ:INCY) reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Incyte announced...
Incyte (NASDAQ:INCY) reported Q1 EPS of $0.55, $0.14 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $728 million versus the consensus estimate of...
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Technology, Basic Materials and Telecoms sectors led shares higher. At the close in NYSE, the...
AbbVie ABBV has submitted regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of its JAK inhibitor drug, Rinvoq (upadacitinib) for the treatment...
Executive SummaryShareholder meetings and conferences ramp up after a busy summer and ahead of the next earnings seasonThe Delta variant forced many companies to quickly switch...
Stocks finally took a break after five days of gains on Tuesday as investors waited on a trio of big tech heavyweights to report after the bell. Meanwhile, the Fed’s...
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 256.17 | 259.22 | 247.74 | +14.93 | +6.19% | 1.34M | NYSE | |||
| 35.18 | 35.87 | 34.96 | -0.35 | -0.99% | 11.41M | NASDAQ | |||
| 1.54 | 1.61 | 0.947 | +0.721 | +88.08% | 20.76M | NASDAQ | |||
| 23.00 | 23.00 | 22.50 | 0.0 | 0.00% | 0.00 | OTC Markets | |||
| 5.67 | 5.95 | 5.53 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 260.96 | 262.56 | 254.83 | +6.27 | +2.46% | 1.51M | NYSE | |||
| 93.41 | 94.50 | 90.37 | -1.07 | -1.13% | 25.57M | NYSE | |||
| 174.33 | 175.40 | 169.17 | +5.66 | +3.36% | 210.90K | NASDAQ | |||
| 15.03 | 18.14 | 14.59 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 35.08 | 35.96 | 34.21 | +0.92 | +2.69% | 2.32M | NYSE | |||
| 171.77 | 171.81 | 170.20 | +1.66 | +0.98% | 6.71M | NASDAQ | |||
| 11.60 | 12.59 | 11.29 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 84.41 | 84.43 | 82.04 | +2.52 | +3.08% | 4.46M | NYSE | |||
| 34.41 | 34.60 | 33.32 | +0.43 | +1.27% | 2.34M | NASDAQ | |||
| 24.35 | 24.45 | 24.23 | +0.15 | +0.64% | 45.32K | NYSE |